Novartis pays $70M upfront to license Chinese biotech’s antitumor drug
Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu.
The Swiss drugmaker will get an exclusive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
